CSF Biomarkers in Longitudinal Alzheimer Disease Cohorts: Pre-Analytic Challenges

被引:1
|
作者
Jonaitis, Erin M. [1 ,2 ,3 ]
Jeffers, Beckie [1 ,2 ,3 ]
VandenLangenberg, Monica [2 ,3 ]
Ma, Yue [2 ]
Van Hulle, Carol [2 ]
Langhough, Rebecca [2 ,3 ]
Du, Lianlian [2 ,4 ]
Chin, Nathaniel A. [3 ]
Przybelski, Robert J. [3 ]
Hogan, Kirk J. [5 ]
Christian, Bradley T. [2 ,6 ,7 ]
Betthauser, Tobey J. [2 ,3 ]
Okonkwo, Ozioma C. [2 ,3 ]
Bendlin, Barbara B. [2 ,3 ]
Asthana, Sanjay [2 ,8 ]
Carlsson, Cynthia M. [1 ,2 ,8 ]
Johnson, Sterling C. [1 ,2 ]
机构
[1] Univ Wisconsin, Wisconsin Alzheimers Inst, Sch Med & Publ Hlth, 600 Highland Ave CSC K6-440 MC4670, Madison, WI 53792 USA
[2] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr & Gerontol, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, Madison, WI 53792 USA
[6] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI 53792 USA
[7] Univ Wisconsin, Sch Med & Publ Hlth, Dept Psychiat, Madison, WI 53792 USA
[8] Wm S Middleton Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI USA
基金
美国国家卫生研究院;
关键词
D O I
10.1093/clinchem/hvad221
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background The sensitivity of amyloid to pre-analytic factors complicates cerebrospinal fluid (CSF) diagnostics for Alzheimer disease. We report reliability and validity evidence for automated immunoassays from frozen and fresh CSF samples in an ongoing, single-site research program.Methods CSF samples were obtained from 2 Wisconsin cohorts (1256 measurements; 727 participants). Levels of amyloid beta 1-42 (A beta 42), phosphorylated tau 181 (pTau181), and total tau (tTau) were obtained using an Elecsys cobas e 601 platform. Repeatability and fixed effects of storage tube type, extraction method, and freezing were assessed via mixed models. Concordance with amyloid positron emission tomography (PET) was investigated with 238 participants having a temporally proximal PET scan.Results Repeatability was high with intraclass correlation (ICC) >= 0.9, but tube type strongly affected measurements. Discriminative accuracy for PET amyloid positivity was strong across tube types (area under the curve [AUC]: A beta 42, 0.87; pTau181A beta 42 , 0.96), although optimal thresholds differed.Conclusions Under real-world conditions, the Elecsys platform had high repeatability. However, strong effects of pre-analytic factors suggest caution in drawing longitudinal inferences.
引用
收藏
页码:538 / 550
页数:13
相关论文
共 50 条
  • [21] Proteomic discovery of CSF biomarkers for Alzheimer's disease
    Zhang, Jing
    Montine, Thomas J.
    ANNALS OF NEUROLOGY, 2007, 61 (05) : 497 - 497
  • [22] Repetitive Blast Injury and CSF Alzheimer Disease Biomarkers
    Alosco, Michael L.
    Tartaglia, Maria Carmela
    NEUROLOGY, 2024, 102 (07)
  • [23] CSF biomarkers in relationship to cognitive profiles in Alzheimer disease
    van der Vlies, A. E.
    Verwey, N. A.
    Bouwman, F. H.
    Blankenstein, M. A.
    Klein, M.
    Scheltens, P.
    van der Flier, W. M.
    NEUROLOGY, 2009, 72 (12) : 1056 - 1061
  • [24] Age and diagnostic performance of Alzheimer disease CSF biomarkers
    Mattsson, N.
    Rosen, E.
    Hansson, O.
    Andreasen, N.
    Parnetti, L.
    Jonsson, M.
    Herukka, S. -K.
    van der Flier, W. M.
    Blankenstein, M. A.
    Ewers, M.
    Rich, K.
    Kaiser, E.
    Verbeek, M. M.
    Rikkert, M. Olde
    Tsolaki, M.
    Mulugeta, E.
    Aarsland, D.
    Visser, P. J.
    Schroeder, J.
    Marcusson, J.
    de Leon, M.
    Hampel, H.
    Scheltens, P.
    Wallin, A.
    Eriksdotter-Jonhagen, M.
    Minthon, L.
    Winblad, B.
    Blennow, K.
    Zetterberg, H.
    NEUROLOGY, 2012, 78 (07) : 468 - 476
  • [25] CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease
    Clifford, D. B.
    Fagan, A. M.
    Holtzman, D. M.
    Morris, J. C.
    Teshome, M.
    Shah, A. R.
    Kauwe, J. S. K.
    NEUROLOGY, 2009, 73 (23) : 1982 - 1987
  • [26] Use of CSF biomarkers in Alzheimer's disease clinical trials
    Blennow, K.
    Zetterberg, H.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (04): : 358 - 361
  • [27] Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease
    Parnetti, Lucilla
    Chiasserini, Davide
    BIOMARKERS IN MEDICINE, 2011, 5 (04) : 479 - 484
  • [28] CSF biomarkers predict rate of cognitive decline in Alzheimer disease
    Kester, M. I.
    van der Vlies, A. E.
    Blankenstein, M. A.
    Pijnenburg, Y. A. L.
    van Elk, E. J.
    Scheltens, P.
    van der Flier, W. M.
    NEUROLOGY, 2009, 73 (17) : 1353 - 1358
  • [29] Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers
    Bernath, Megan M.
    Bhattacharyya, Sudeepa
    Nho, Kwangsik
    Barupal, Dinesh Kumar
    Fiehn, Oliver
    Baillie, Rebecca
    Risacher, Shannon L.
    Arnold, Matthias
    Jacobson, Tanner
    Trojanowski, John Q.
    Shaw, Leslie M.
    Weiner, Michael W.
    Doraiswamy, P. Murali
    Kaddurah-Daouk, Rima
    Saykin, Andrew J.
    NEUROLOGY, 2020, 94 (20) : E2088 - E2098
  • [30] CSF metabolites associated with biomarkers of Alzheimer's disease pathology
    Dong, Ruocheng
    Lu, Qiongshi
    Kang, Hyunseung
    Suridjan, Ivonne
    Kollmorgen, Gwendlyn
    Wild, Norbert
    Deming, Yuetiva
    Van Hulle, Carol A.
    Anderson, Rozalyn M.
    Zetterberg, Henrik
    Blennow, Kaj
    Carlsson, Cynthia M.
    Asthana, Sanjay
    Johnson, Sterling C.
    Engelman, Corinne D.
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15